- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Osteoporosis
The Endocrinology Network® Osteoporosis clinical resource center is our hub for the latest in bone health and management of fracture risk. With a fracture causing significant increases in risk of mortality, management of osteoporosis represents a crucial aspect of care. This page will offer the latest information related to FDA approvals, new studies, and guideline updates pertaining to diagnosis and management of osteoporosis.
High Levels of Body Fat Linked to Increased Osteoporosis Risk in Men
February 10, 2022
Using data from NHANES, researchers at the University of Chicago provide insight into associations of fat mass index and lean mass index on bone mineral density and how sex influences these associations.
Comparing Fracture Risk with Risedronate vs Alendronate During Drug Holidays
January 18, 2022
An analysis of data from more than 50k patients using risedronate or alendronate from Ontario compares the risk of hip fracture and other outcomes during drug holidays.
Endocrine Month in Review: November 2021
November 27, 2021
November's endocrine month in review features stories on the Build Back Better Act, a recent review from the IOF, data from Kidney Week 2021, and more.
International Osteoporosis Foundation Issues Review of Links Between Bone Loss and Vascular Calcification
November 18, 2021
The latest review from the International Osteoporosis Foundation is a 14-page document with more than 100 references outlining current data related to the pathophysiological links between vascular calcification and bone loss.
Endocrine Month in Review: October 2021
October 30, 2021
October's endocrine month in review features stories on the new ADA and EASD type 1 diabetes guidance, a phase 2 trial examining oral PTH tablets for osteoporosis, and a 3-part panel discussion focusing on diabetes management in 2021.
No Increase in Fracture Risk from SGLT2 Inhibitor Use, Study Finds
October 29, 2021
A propensity score-matched analysis comparing fracture risk associated with the initiation of SGLT2 inhibitors versus GLP-1RAs or DPP-4 inhibitors indicates use of SGLT2 inhibitors was not associated with an increase in risk of fractures in older patients with type 2 diabetes.
Patients with Diabetes Remain at Increased Fracture Risk, Despite Declines in Overall Population
October 07, 2021
An analysis of more than 1.2 million patients who experienced a fracture from 1997-2017 provides insight into contemporary trends in fracture incidence rates based on presence of diabetes.
PTH Tablets Could Provide Oral Option for Osteoporosis Management
October 06, 2021
A phase 2 trial presented at ASBMR provides insight into the effects of oral PTH tablets on bone health among postmenopausal women with osteoporosis.
Use of Alendronate Could Lower Odds of Developing Type 2 Diabetes
September 28, 2021
An analysis of patient data from a national registry in Denmark indicates use of alendronate was associated with reductions in odds of developing type 2 diabetes, with this reduction becoming greater with longer use of the osteoporosis medication.